Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?

AbstractPurpose of ReviewAs outcomes for patients with early-stage breast cancer have improved, oncologists have sought to de-escalate systemic therapy to minimize toxicities while maintaining robust clinical outcomes. This review summarizes current strategies to de-escalate systemic therapy in early-stage breast cancer.Recent FindingsDe-escalation has emerged as an option for some patients with early-stage breast cancer. Recent studies in HERAbstract_Para2-positive breast cancer support de-escalating neoadjuvant regimens with paclitaxel and dual HER2 blockage with additional therapy based on response to chemotherapy. In ER-positive breast cancer, the routine use of genomic testing has identified patients who can be treated with endocrine therapy alone. De-escalation clinical trials in triple-negative breast cancer are sparse; however, prognostic biomarkers may allow de-escalation in select patients.SummaryDe-escalation trials are working toward a tailored personalized medicine approach by selecting the best therapy for each patient focused on optimized clinical outcomes and quality of life.
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research